MedPath

Phase I/II study of intravenous and intraperitoneal paclitaxel combined with continuous intraperitoneal cisplatin for advanced gastric cancer with peritoneal metastasis

Phase 1
Conditions
advanced gastric cancer with peritoneal metastasis
Registration Number
JPRN-UMIN000002257
Lead Sponsor
Department of Surgical Oncology, The University of Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
25
Inclusion Criteria

Not provided

Exclusion Criteria

Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety the 1-year overall survival rate
Secondary Outcome Measures
NameTimeMethod
the overall response rate, efficacy against peritoneal metastasis and safety
© Copyright 2025. All Rights Reserved by MedPath